Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Researchers presented findings of a significantly higher 5-year OS rate in patients who received 4 cycles of eBEACOPP compared with patients who received 6/8 cycles.
Modifications of ABVD or CHOP were common among elderly patients with cHL and may contribute to their disproportionate excess mortality, signaling a need for less toxic regimens.
Inotuzumab ozogamicin instead of gemcitabine added to R-CVP did not improve OS or PFS, but less toxicity among patients with untreated DLBCL with comorbid conditions.
Researchers conducted a multicenter, retrospective analysis of outcomes for 1360 patients who were treated with RT with or without nonanthracycline-based CT.
Obinutuzumab plus chemotherapy showed more durable efficacy, safety, and longer progression-free survival for patients with untreated follicular lymphoma.
